Candida glabrata: Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen

Area of Science:

• Medical Mycology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Candida glabrata is a significant cause of hematogenously disseminated candidiasis (HDC), particularly in the United States.
• There has been a documented increase in C. glabrata infections and fluconazole resistance since 1992.
• While generally less virulent than Candida albicans, C. glabrata's virulence is being re-evaluated.

Purpose of the Study:

• To highlight the increasing prevalence of antifungal resistance in Candida glabrata.
• To draw attention to the emergence of multidrug resistance (MDR) in C. glabrata clinical isolates.
• To underscore the clinical significance of co-resistance to azoles and echinocandins.

Main Methods:

• Analysis of epidemiological data on C. glabrata infections and antifungal resistance trends.
• Review of recent findings on genetic mutations (e.g., CgPdr1p GOF mutations) affecting C. glabrata.
• Examination of clinical isolate data from multicenter surveys.

Main Results:

• Increased frequency of C. glabrata as a cause of HDC and rising fluconazole resistance in the US since 1992.
• Gain-of-function mutations in CgPdr1p confer azole resistance and enhance C. glabrata fitness and virulence.
• Emergence of multidrug resistance (MDR) and co-resistance to azoles and echinocandins in clinical C. glabrata isolates.

Conclusions:

• Candida glabrata poses a growing threat due to increasing antifungal resistance and virulence.
• Genetic modifications are driving the emergence of MDR in C. glabrata.
• Co-resistance to major antifungal classes necessitates urgent clinical attention and therapeutic strategy development.